BMY-28100 IN RESPIRATORY INFECTION

• Published in: CHEMOTHERAPY Vol. 37; no. Supplement3; pp. 409 - 414
• Main Authors: MIYAHARA, SATOKO, HAYASHI, TOKIKO, MAEDA, FUMIHIKO, SEKI, MASAHIKO, SENJU, SHOUJI, YOSHIDA, MINORU, TOYOSHIMA, HIDEO, YANO, ATSUSHI, ARITOMI, TAKAMICHI, IKEDA, AKIHITO
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1989; 公益社団法人 日本化学療法学会
• Subjects: BMY-28100; 呼吸器感染症; 臨床的検討
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.37.Supplement3_409

We studied the clinical efficacy, bacteriological effect and safety of a new antibiotic, BMY-28100, in respiratory infections. The efficacy of BMY-28100 was clinically evaluated in 18 cases of respiratory infection including 12 cases of acute bronchitis, 4 of bacterial pneumonia, and 2 of chronic respiratory failure with acute exacerbation by respiratory infection. The causative organisms were revealed in 14 cases: Haemophilus influenzae in 6, H, influenzae plus Streptococcus pneumaniae in 1, S. pneumoniae in 2, Pseudomonas aeruginosa in 2, Klebsiella pneumaniae in 2 and Xanthomonas maltophilia in 1. The clinical efficacy rate was 70.6% in all patients. As an adverse reaction, slight elevation of GOT and GPT was found in 2 cases.